Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
ANIX Anixa Biosciences	$3.23 +8.4%	$3.34	$2.75 ▼ $5.13	$95.06M	0.84	142,823 shs	232,647 shs
NERV Minerva Neurosciences	$2.44 +0.4%	$3.23	$2.29 ▼ $13.49	$17.03M	0.21	99,925 shs	4,157 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A
ZYNE Zynerba Pharmaceuticals	$1.30 +2.4%	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	862,700 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-86.58%
ANIX Anixa Biosciences	-6.29%	-3.87%	-4.79%	-31.96%	-29.88%
NERV Minerva Neurosciences	-2.78%	-2.39%	-4.67%	-69.90%	-5.77%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+246.57%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANIX Anixa Biosciences	1.9378 of 5 stars	3.5	3.0	0.0	0.0	0.7	3.3	0.0
NERV Minerva Neurosciences	3.6126 of 5 stars	3.0	5.0	0.0	4.6	1.8	0.0	0.0
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
ANIX Anixa Biosciences	3.00	Buy	$12.00	271.52% Upside
NERV Minerva Neurosciences	2.00	Hold	$11.00	351.47% Upside
OTIC Otonomy	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	2.00	Hold	$1.11	-14.62% Downside

Current Analyst Ratings

Latest OTIC, ADMP, ANIX, NERV, and ZYNE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2024	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
2/27/2024	NERV Minerva Neurosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$11.00
2/13/2024	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
ANIX Anixa Biosciences	$210K	490.65	N/A	N/A	$0.75 per share	4.31
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($4.07) per share	N/A
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
ANIX Anixa Biosciences	-$9.81M	-$0.34	N/A	N/A	N/A	N/A	-44.09%	-40.90%	6/12/2024 (Estimated)
NERV Minerva Neurosciences	-$30M	-$4.65	N/A	N/A	N/A	N/A	N/A	-50.27%	5/20/2024 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest OTIC, ADMP, ANIX, NERV, and ZYNE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q1 2024	ANIX Anixa Biosciences	-$0.09	-$0.10	-$0.01	-$0.10	N/A	N/A
2/22/2024	Q4 2023	NERV Minerva Neurosciences	-$0.88	-$1.19	-$0.31	-$1.19	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
ANIX Anixa Biosciences	N/A	15.19	15.19
NERV Minerva Neurosciences	N/A	12.57	12.58
OTIC Otonomy	N/A	1.74	1.74
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
ANIX Anixa Biosciences	29.13%
NERV Minerva Neurosciences	34.56%
OTIC Otonomy	41.23%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
ANIX Anixa Biosciences	22.60%
NERV Minerva Neurosciences	6.40%
OTIC Otonomy	1.09%
ZYNE Zynerba Pharmaceuticals	13.04%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
ANIX Anixa Biosciences	4	31.90 million	24.69 million	Optionable
NERV Minerva Neurosciences	9	6.99 million	6.55 million	Not Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

OTIC, ADMP, ANIX, NERV, and ZYNE Headlines

Source	Headline
	Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results finance.yahoo.com - October 31 at 7:57 AM
	Why Shares of Harmony Bioscience Are Falling on Friday fool.com - October 13 at 12:59 PM
	New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies markets.businessinsider.com - October 11 at 9:47 AM
	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE finance.yahoo.com - October 11 at 9:47 AM
	H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 10 at 1:59 PM
	Analysts: ZYNE stock price target of $1.25 in 12 months knoxdaily.com - October 5 at 6:47 PM
	Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions finance.yahoo.com - October 4 at 7:33 PM
	Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 2 at 3:14 PM
	20 Countries With Highest Rate of Epilepsy finance.yahoo.com - September 29 at 6:24 PM
	Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 finance.yahoo.com - September 29 at 1:23 PM
	Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal bizjournals.com - September 27 at 2:42 PM
	Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise knoxdaily.com - September 25 at 8:15 PM
	Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright knoxdaily.com - September 20 at 12:12 PM
	Negative sentiment towards ZYNE reflected in surge in short interest knoxdaily.com - September 15 at 8:27 PM
	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc finance.yahoo.com - September 14 at 11:23 PM
	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium finance.yahoo.com - September 14 at 6:23 PM
	Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement law.com - September 11 at 4:04 PM
	Positive sentiment towards ZYNE reflected in decline in short interest knoxdaily.com - September 8 at 5:19 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR bakersfield.com - August 31 at 5:00 PM
	HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE) msn.com - August 16 at 4:20 AM
	Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout biospace.com - August 15 at 6:19 PM
	Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much? dhakatribune.com - August 15 at 6:19 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - August 15 at 6:19 PM
	Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
3 Computer Vision Stocks for Long-Term Gains From AI
April 16, 2024 6:08 AM
View 3 Computer Vision Stocks for Long-Term Gains From AI
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
Intuitive Surgical Leads the Robotic Surgery Movement
April 22, 2024 6:10 AM
View Intuitive Surgical Leads the Robotic Surgery Movement

All Headlines

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Anixa Biosciences

NASDAQ:ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Minerva Neurosciences

NASDAQ:NERV

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Zynerba Pharmaceuticals

NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial